Introduction
Refractory epilepsy is a challenging aspect of pediatric epilepsy and there remain many patients who are refractory to new and advantageous antiepileptic drugs. 1 However, surgery is beneficial to a limited number of these patients. 2 Hence, one available option is from dietary treatments. The classic ketogenic diet (KD) is effective in over a 90% seizure frequency reduction in one-third of patients with refractory epilepsy 3 ; however, there are several limitations to its availability, implementation, and maintenance. [4] [5] [6] [7] Considering this, alternative treatments are necessary. The Low Glycemic Index Treatment (LGIT) and the Modified Atkins Diet (MAD) are diets recently introduced for refractory epilepsy. 5, 7 LGIT has an antiepileptic efficacy comparable to KD with fewer side effects.
Purpose: Intractable epilepsy is a challenging aspects of pediatric epilepsy. This study was conducted to determine the efficacy and tolerability of Low Glycemic Index Treatment (LGIT) in pediatric patients referred to a Children's Hospital in Iran with intractable epilepsy. Methods: We studied 42 children with refractory epilepsy aged between 1.5 and 17 years of age, from October 2009 to April 2011 in the pediatric neurology department of Mofid Children's Hospital. Patient information on clinical status, seizure type, and baseline frequency, blood and urine biochemistry, neuro-imaging and the EEG were collected.
LGIT was initiated on an outpatient basis and the diet was composed of 65% fat, 25% protein and 10% carbohydrate (40-60 g), and the glycemic index of foods was limited to below 50. Results: 84% of patients were categorized as having more than one seizure per day at study entry, with the remaining children as experiencing over one seizure per week. A greater than 50% seizure reduction was observed in 71.4% of the patients after the second week, in 73.8% at the end of the first month and in 77.8% at the end of the second month. In 30% of the patients a mild increase in blood urea nitrogen (BUN) was detected. The most important reasons for discontinuation of LGIT were restrictiveness, lack of satiation and excessive meat in this diet. No significant complications were observed during the administration of the diet.
Conclusion:
LGIT is a safe and effective adjuvant antiepileptic therapy and may be used as an alternative to the ketogenic diet in conditions when this diet cannot be used. ß 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
seizure frequency due to loss of follow up; (2) a history of treatment with the KD in the previous 5 months because of the residual effects of KD on seizure controls; and, lastly, (3) a history of metabolic or nephrologic problems. The patients and their parents were educated by the dietician regarding the restriction of carbohydrates with high glycemic index (GI > 50) and limiting total carbohydrates to 40-60 g/day (roughly 10% of daily calories). 7 Patient height, weight, and Laboratory assessments (blood glucose, b-hydroxybutyrate, blood urea nitrogen (BUN), creatinine, triglyceride, cholesterol, serum transaminases, urine specific gravity, and ketone bodies with urine Ca/Cr ratio) at baseline and at each follow-up visit were documented. A neurologist documented seizure type, baseline seizure frequency, and prior and current antiepileptic drugs. All possible side effects were questioned during follow up visits.
Results
The 42 patients included in this study were aged between 1.5 and 17 years of age (mean, 5.6 AE 3.2 years), with an equal number of male and female patients. All patients were considered to have refractory epilepsy with a history of more than three antiepileptic drugs without effective seizure control. While on the diet, patients consumed 2-4 (mean 2.9 AE 0.6) AEDs. Seizure frequency was between one seizure per week to over 100 seizures per day with a median of 3.00 per day. The duration of LGIT was between 4 and 44 weeks (mean 15.3 AE 11.2 weeks; median 12.0).
The aetiologies of epilepsy were cryptogenic (59%), sequela of remote insult (24%), structural anomalies (7%), and idiopathic (10%).
Mean seizure frequencies at weeks 2, 4, and 8 after treatment started were significantly lower than the baseline (p < 0.001) with reduction rates of 56%, 61%, and 67%, respectively. Fig. 1 depicts the percentage of patients according to the percent of seizure reduction for each given interval. The efficacy of seizure reduction (>50%) was 71.4%, 73.8%, and 77.8% after 2, 4, and 8 weeks, respectively. The percentage of seizure free patients increased to 9.5%, 14.3%, and 16.6% at weeks 2, 4 and 8, respectively, with increasing duration of treatment. Seizure type did not have a significant effect on efficacy (p = 0.75). There was no correlation between the age, sex, type, and aetiology of seizure, EEG, and imaging findings with the effectiveness of LGIT (p = 0.70, p = 0.19, p = 0.75, p = 0.44, p = 0.60, and p = 0.85, respectively).
Reasons for discontinuation of the diet were as follows: restrictiveness (n = 8); lack of satiation (n = 7); premature discontinuation due to orders of physicians out of our centre who were unfamiliar with the diet (n = 5); unpalatability of the diet (n = 3); dissatisfaction of parents with the amount of efficacy (n = 3); and shifting to surgical options (callosotomy, n = 1). There was no notable change in drug regimen for patients during treatment. No significant complications during the course of treatment were reported, except for a 4-year-old child that had a previous history of nephrolithiasis that led to treatment discontinuation after 18 weeks of treatment and despite significant seizure reduction.
Baseline and follow-up assessments of serum glucose, BUN, creatinine, triglycerides, cholesterol, AST, and ALT levels were available for 15 patients (Table 1) .
Serum ketone bodies were available in two patients with normal results (0.1 and 0.2 mmol/dl). Urine ketone bodies were also quantitatively analyzed in 12 patients and 3 patients had +1 ketone bodies detected in their urine. The mean urine specific gravity in these patients revealed a relative increase of urine concentration (specific gravity = 1.023).
It needs to be mentioned that these results had been obtained from different laboratories.
Discussion
Our findings suggest that LGIT can reduce seizure frequency in a large number of patients with refractory epilepsy. Following a oneyear course of follow up, Muzykewics et al. 6 found an over 50% reduction in up to 66% of their patients when compared to baseline seizure frequency. They also found that lower glucose levels were associated with better seizure control with no correlation with serum ketone bodies. Coppola et al. 8 also indicated that 8 of their 15 (53.3%) patients experienced a 50-90% seizure reduction after a mean follow up period of 14.5 AE 6.5 months. Their findings confirmed the association between plasma glucose levels and seizure control reported by Muzykewics et al. 6 Pfeifer et al. have suggested that it is the reduced blood glucose, and not the level of ketosis that produces the anti-epileptic effect of KD and LGIT. 4 Our study found no association between random glucose levels and seizure control. However, the results obtained were from different laboratories and we had limitations in testing serum ketone bodies. Muzykewics et al. 6 found elevated serum BUN levels in more than one-third of the patients, as we observed in our study. In our experience, LGIT had fewer side effects when compared to KD, a characteristic that is of great value for young children. In this study, we observed a 12.6% increase in serum triglycerides without significant metabolic implication, an increase close to 12.5% as reported by Thibert et al. 9 and attributed to high fat content in the diet. It was assumed that this increase in triglyceride levels will not be a disadvantage for LGIT, because the highest triglyceride level detected was 150 mg/dl (within the normal range). Although we observed elevated BUN levels in approximately one-third of patients that were probably the result of protein intake, there is likely no relationship between excessive protein intake and kidney failure in normal subjects. Hence, preexisting renal failure is a contraindication of LGIT diet. Elevated urine specific gravity in our patients may have also increased BUN levels. Therefore, it is recommended that LGIT patients be closely followed for renal function, higher fluid intake, and modifications in protein intake if necessary. In our study, in terms of compliance and tolerability, LGIT was more palatable and better tolerated than KD. However, despite the restrictiveness of KD, a similar study conducted earlier at our centre on KD patients showed that they stayed on the treatment for a longer duration, 10 a difference with several explanations. First, KD patients are hospitalized, which provides them with sufficient time for education and availability of the emergent medical intervention to relieve anxiety and leads to greater parental confidence. However, in LGIT, this intervention is absent and may cause early treatment discontinuation. Parents consider KD a last resort in the treatment of their child's refractory epilepsy and they rigidly follow the instructions for KD. Finally, the effect of KD appears earlier than LGIT, which provides a strong motivation to continue treatment. [10] [11] [12] In conclusion, LGIT was better tolerated and more palatable than KD. Easy preparation without detailed meal plans and weighing food on a gram scale, increased palatability because of more liberalized carbohydrate content and decreased fat content are some advantages of LGIT. Finally, yet importantly, we may add fewer psychosocial issues as the normality of the foods and ability of the patients to eat outside the home without the need to prepare special meals. The low cost of the outpatient implementation of
LGIT is a main advantage of this treatment. However, this is at the expense of less than optimal intervention and communication with patients and parents.
Based on these observations, it may be better for some patients and in some special situations to introduce LGIT in a hospital setting with a primary fasting state like KD.
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